Nanovibronix Inc (NAOV)

$0.53

+0.01

(+0.95%)▲

Live

Performance

  • $0.50
    $0.56
    $0.53
    downward going graph

    5.45%

    Downside

    Day's Volatility :10.52%

    Upside

    5.36%

    downward going graph
  • $0.46
    $1.55
    $0.53
    downward going graph

    13.68%

    Downside

    52 Weeks Volatility :70.48%

    Upside

    65.8%

    downward going graph

Returns

PeriodNanovibronix IncIndex (Russel 2000)
3 Months
-27.75%
0.0%
6 Months
-29.59%
0.0%
1 Year
-47.01%
0.0%
3 Years
-98.4%
-23.0%

Highlights

Market Capitalization
1.4M
Book Value
$1.02
Earnings Per Share (EPS)
-1.29
PEG Ratio
0.0
Wall Street Target Price
10.5
Profit Margin
-83.49%
Operating Margin TTM
-82.5%
Return On Assets TTM
-29.57%
Return On Equity TTM
-140.59%
Revenue TTM
3.4M
Revenue Per Share TTM
1.5
Quarterly Revenue Growth YOY
177.89999999999998%
Gross Profit TTM
167.0K
EBITDA
-2.3M
Diluted Eps TTM
-1.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Nanovibronix Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1881.13%

Current $0.53
Target $10.50

Company Financials

FY18Y/Y Change
Revenue
318.0K
↑ 33.05%
Net Income
-4.2M
↓ 16.33%
Net Profit Margin
-1.3K%
↑ 771.12%
FY19Y/Y Change
Revenue
530.0K
↑ 66.67%
Net Income
-5.8M
↑ 39.48%
Net Profit Margin
-1.1K%
↑ 213.08%
FY20Y/Y Change
Revenue
623.0K
↑ 17.55%
Net Income
-4.3M
↓ 25.34%
Net Profit Margin
-694.38%
↑ 398.83%
FY21Y/Y Change
Revenue
1.7M
↑ 172.07%
Net Income
-14.3M
↑ 230.14%
Net Profit Margin
-842.6%
↓ 148.22%
FY22Y/Y Change
Revenue
752.0K
↓ 55.63%
Net Income
-5.4M
↓ 61.85%
Net Profit Margin
-724.47%
↑ 118.13%
FY23Y/Y Change
Revenue
2.3M
↑ 203.59%
Net Income
-3.7M
↓ 31.88%
Net Profit Margin
-162.55%
↑ 561.92%
Q1 FY23Q/Q Change
Revenue
-102.0K
↑ 0.0%
Net Income
-2.1M
↑ 0.0%
Net Profit Margin
2.0K%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
294.0K
↓ 388.24%
Net Income
-1.1M
↓ 47.84%
Net Profit Margin
-365.31%
↓ 2383.94%
Q3 FY23Q/Q Change
Revenue
458.0K
↑ 55.78%
Net Income
-727.0K
↓ 32.31%
Net Profit Margin
-158.73%
↑ 206.58%
Q4 FY23Q/Q Change
Revenue
1.2M
↑ 156.99%
Net Income
-813.0K
↑ 11.83%
Net Profit Margin
-69.07%
↑ 89.66%
Q1 FY24Q/Q Change
Revenue
921.0K
↓ 21.75%
Net Income
-588.0K
↓ 27.68%
Net Profit Margin
-63.84%
↑ 5.23%
Q2 FY24Q/Q Change
Revenue
817.0K
↓ 11.29%
Net Income
-688.0K
↑ 17.01%
Net Profit Margin
-84.21%
↓ 20.37%
FY18Y/Y Change
Total Assets
1.6M
↓ 67.52%
Total Liabilities
1.1M
↓ 9.26%
FY19Y/Y Change
Total Assets
2.0M
↑ 28.86%
Total Liabilities
688.0K
↓ 38.41%
FY20Y/Y Change
Total Assets
8.2M
↑ 304.17%
Total Liabilities
5.8M
↑ 748.11%
FY21Y/Y Change
Total Assets
8.6M
↑ 4.78%
Total Liabilities
2.3M
↓ 60.43%
FY22Y/Y Change
Total Assets
5.9M
↓ 31.81%
Total Liabilities
2.6M
↑ 14.6%
FY23Y/Y Change
Total Assets
6.7M
↑ 13.52%
Total Liabilities
2.7M
↑ 1.51%
Q1 FY23Q/Q Change
Total Assets
5.9M
↑ 0.0%
Total Liabilities
2.6M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
3.8M
↓ 34.84%
Total Liabilities
2.7M
↑ 0.76%
Q3 FY23Q/Q Change
Total Assets
7.4M
↑ 92.14%
Total Liabilities
2.7M
↑ 0.19%
Q4 FY23Q/Q Change
Total Assets
6.7M
↓ 9.33%
Total Liabilities
2.7M
↑ 0.56%
Q1 FY24Q/Q Change
Total Assets
6.2M
↓ 6.58%
Total Liabilities
2.7M
↑ 1.68%
Q2 FY24Q/Q Change
Total Assets
5.7M
↓ 8.64%
Total Liabilities
2.9M
↑ 4.54%
FY18Y/Y Change
Operating Cash Flow
-3.6M
↑ 62.69%
Investing Cash Flow
-8.0K
↑ 0.0%
Financing Cash Flow
94.0K
↓ 98.54%
FY19Y/Y Change
Operating Cash Flow
-3.9M
↑ 9.13%
Investing Cash Flow
-2.0K
↓ 75.0%
Financing Cash Flow
4.3M
↑ 4491.49%
FY20Y/Y Change
Operating Cash Flow
-3.4M
↓ 12.47%
Investing Cash Flow
-2.0K
↑ 0.0%
Financing Cash Flow
9.5M
↑ 120.62%
FY21Y/Y Change
Operating Cash Flow
-4.4M
↑ 28.78%
Investing Cash Flow
-3.0K
↑ 50.0%
Financing Cash Flow
4.6M
↓ 51.9%
FY22Y/Y Change
Operating Cash Flow
-7.0M
↑ 61.09%
Investing Cash Flow
-3.0K
↑ 0.0%
Financing Cash Flow
2.1M
↓ 54.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.3M
↑ 0.0%
Investing Cash Flow
-1000.0
↓ 200.0%
Financing Cash Flow
2.1M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Nanovibronix Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nanovibronix Inc
Nanovibronix Inc
-21.71%
-29.59%
-47.01%
-98.4%
-99.11%
Stryker Corporation
Stryker Corporation
0.83%
12.78%
40.21%
33.69%
71.83%
Boston Scientific Corp.
Boston Scientific Corp.
4.85%
29.48%
75.68%
96.28%
127.87%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.32%
-19.19%
1.77%
-39.29%
-7.22%
Abbott Laboratories
Abbott Laboratories
3.99%
11.51%
24.65%
-4.53%
46.22%
Medtronic Plc
Medtronic Plc
2.65%
14.48%
27.42%
-24.18%
-13.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nanovibronix Inc
Nanovibronix Inc
NA
NA
0.0
0.0
-1.41
-0.3
NA
1.02
Stryker Corporation
Stryker Corporation
40.15
40.15
2.64
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
70.26
70.26
2.14
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.67
27.67
3.65
2.6
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.83
35.83
4.31
4.67
0.14
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
30.23
30.23
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nanovibronix Inc
Nanovibronix Inc
Buy
$1.4M
-99.11%
NA
-83.49%
Stryker Corporation
Stryker Corporation
Buy
$137.1B
71.83%
40.15
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$127.3B
127.87%
70.26
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.3B
-7.22%
27.67
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$205.1B
46.22%
35.83
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.2B
-13.49%
30.23
12.06%

Insights on Nanovibronix Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.17M → 817.0K (in $), with an average decrease of 16.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -588.0K → -688.0K (in $), with an average decrease of 17.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 125.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 194.7%

Institutional Holdings

  • Armistice Capital, LLC

    4.92%

  • Vanguard Group Inc

    1.08%

  • Geode Capital Management, LLC

    0.83%

  • Renaissance Technologies Corp

    0.77%

  • Citadel Advisors Llc

    0.55%

  • Tower Research Capital LLC

    0.22%

Company Information

nanovibronix inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. the company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. this unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. the company's patch based product diagnosis, painshield®, carries an fda clearance. nanovibronix catheter based products include the cathbottm . nanovibronix inc. is located in elmsford, ny. its subsidiary, nanovibronix ltd. is located in nesher, israel.

Organization
Nanovibronix Inc
Employees
10
CEO
Mr. Brian M. Murphy
Industry
Health Technology

Discover More

FAQs